

Action/Amend B
#10
3/24/02
Patent
Attorney Docket: 270/228

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Cynthia K. French, et al.

Serial No.: 09/680,121

Filed: October 4, 2000

For: PROSTATE CANCER-SPECIFIC
MARKER

Group Art Unit: 1642

Examiner: Gary B. Nickol

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Restriction/Election requirement, Applicants select Group I without traverse. Please cancel claims 41, 46-47 and 51-55 without prejudice. Additionally, please amend claims 42, 43 and 48 as follows:

B₁ 42. The polynucleotide of claim 39 wherein the nucleotide sequence encodes an immunogenic Repro-PC-1.0 polypeptide.

48. A recombinant polynucleotide comprising an expression control sequence operably linked to a nucleotide sequence encoding:

a Repro-PC-1.0 polypeptide,

a polynucleotide probe or primer of at least 40 nucleotides that specifically hybridizes to a nucleotide sequence selected from Repro-PC-1.0 cDNA (SEQ ID NO:1) or its complement, or

OC-103360.1

CERTIFICATE OF TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being transmitted via facsimile ((703) 308-4315) on the date shown below to the Commissioner for Patents, Washington, DC 20231.

February 11, 2002
Date of Transmission

Lynne Fulmer
Lynne Fulmer